checkAd
    Karolinska Development (B) Aktie
    0,1090
     
    EUR
    +0,18 %
    +0,0002 EUR
    Letzter Kurs 10.05.24 Frankfurt
    0,1276
     
    EUR
    15.700 STK
    Geldkurs 10.05.24
    0,1638
     
    EUR
    18.400 STK
    Briefkurs 10.05.24
    ISIN: SE0002190926 · WKN: A0M84G · SYM: 2I9 · Schweden

    Neueste Nachrichten

    Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
    08.05.24 · globenewswire · Karolinska Development (B)
    Interim Report - January-March 2024
    26.04.24 · globenewswire · Karolinska Development (B)
    Notice of Annual General Meeting in Karolinska Development AB (publ)
    16.04.24 · globenewswire · Karolinska Development (B)
    Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
    22.03.24 · globenewswire · Karolinska Development (B)
    Karolinska Development Annual Report 2023 published
    22.03.24 · globenewswire · Karolinska Development (B)
    Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
    14.03.24 · globenewswire · Karolinska Development (B)
    Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units
    14.03.24 · globenewswire · Karolinska Development (B)
    Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD
    06.03.24 · globenewswire · Karolinska Development (B)
    Year-end Report - January-December 2023
    16.02.24 · globenewswire · Karolinska Development (B)
    Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round
    17.01.24 · globenewswire · Karolinska Development (B)
    Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product
    09.01.24 · globenewswire · Karolinska Development (B)
    Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis
    28.11.23 · globenewswire · Karolinska Development (B)